As a clinician scientist, I get really excited about helping sponsors develop new treatments for patients. For some diseases, the lack of a validated prognostic biomarker is an impediment to developing effective treatments. In this blog post, I’ll discuss how we worked with the Critical Path Institute (C-Path) Polycystic Kidney Disease Outcomes Consortium to gain […]Read More
Author: Samer Mouksassi
Dr. Mouksassi started his clinical pharmacology career serving as a clinical pharmacist in a research hospital where he led the development of a Therapeutic Drug Monitoring service using Bayesian Feedback. His research focused on developing population pharmacokinetics/pharmacodynamics models to help clinicians to select the best dose for pediatric patients. Since joining Certara in 2007, he’s helped sponsors apply model-based drug development for more than a hundred studies. These contributions generated more than 60 abstracts/manuscripts in the field of pharmacometrics spanning numerous therapeutic areas. Dr. Mouksassi earned his PhD in pharmaceutical sciences from the University of Montreal, Faculty of Pharmacy and is a fellow of the American College of Clinical Pharmacology. He earned his PharmD from the Lebanese University in 2003.